-+ 0.00%
-+ 0.00%
-+ 0.00%

Pliant doses first patient in Phase 1b FORTIFY trial of PLN-101095 combo therapy

PUBT·04/30/2026 12:39:33
Listen to the news
Pliant doses first patient in Phase 1b FORTIFY trial of PLN-101095 combo therapy
  • Pliant Therapeutics dosed first participant in FORTIFY, a Phase 1b indication-expansion study of PLN-101095 combined with pembrolizumab in immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.
  • Trial will assess safety profile, drug behavior in body, tolerability, and early signs of anti-tumor activity; no clinical results have been presented yet.
  • Study design starts with 14 days of PLN-101095 monotherapy at 1,000 mg twice daily, then adds pembrolizumab as combination therapy.
  • Enrollment is underway; interim data are expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300830PRIMZONEFULLFEED9710175) on April 30, 2026, and is solely responsible for the information contained therein.